2. JAK/STAT Signaling Protein Tyrosine Kinase/RTK
  3. EGFR
  4. Dacomitinib hydrate

Dacomitinib hydrate  (Synonyms: PF-00299804 hydrate; PF-299804 hydrate)

Cat. No.: HY-118263 Purity: 99.54%
COA
SDS
Handling Instructions Technical Support

Dacomitinib (PF-00299804) hydrate is an orally active, irreversible pan-ErbB inhibitor. Dacomitinib hydrate can be used in the research of cancers such as metastatic non-small cell lung cancer (NSCLC).

For research use only. We do not sell to patients.

CAS No. : 1042385-75-0

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMF
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMF In-stock
Solid
5 mg In-stock
10 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 29 publication(s) in Google Scholar

Other Forms of Dacomitinib hydrate:

Dacomitinib hydrate Related Antibodies

Top Publications Citing Use of Products
Cell Proliferation/Viability Assay
WB
In Vivo Efficacy Study
Flow Cytometry
Cell Imaging/Staining

    Dacomitinib hydrate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 9:e07524.  [Abstract]

    Dacomitinib (7 mg/kg, i.g.) largely improved the radiosensitivity of subcutaneous xenograft tumors.

    Dacomitinib hydrate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 9:e07524.  [Abstract]

    The combination of Dacomitinib (7 mg/kg, i.g.) and IR induced much more cell death than either IR or dacomitinib alone.

    Dacomitinib hydrate purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Aug 19;44(1):245.  [Abstract]

    Primary gastric cancer (GC-1 and GC-2) cells treated with Pyrotinib, Dacomitinib, Afatinib, or DMSO (control) at 1 µM concentration over 3 days, growth curves represent three independent experiments.

    Dacomitinib hydrate purchased from MedChemExpress. Usage Cited in: Molecules. 2024 Jan 4;29(1):274.

    SKOV3-TR cells were treated with combination of Dacomitinib (0, 0.1, 0.5, and 1 µM) and Paclitaxel (0, 10, 100, and 200 nM) as indicated for 48 h, and then cleaved PARP was analyzed by immunoblotting.

    Dacomitinib hydrate purchased from MedChemExpress. Usage Cited in: Molecules. 2024 Jan 4;29(1):274.

    SKOV3-TR cells were subjected to treatments with DMSO (Mock), 200 nM paclitaxel, 1 µM Dacomitinib, and combination of 200 nM Paclitaxel and 1 µM Dacomitinib each for 48 h. Apoptotic cell death was analyzed by FACS analysis.

    View All EGFR Isoform Specific Products:

    View All Isoforms
    EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Dacomitinib (PF-00299804) hydrate is an orally active, irreversible pan-ErbB inhibitor. Dacomitinib hydrate can be used in the research of cancers such as metastatic non-small cell lung cancer (NSCLC)[1].

    Cellular Effect
    Cell Line Type Value Description References
    Sf9 IC50
    46 nM
    Compound: 25, PF-00299804
    Inhibition of GST-tagged ErbB2 expressed in sf9 cells by ELISA
    Inhibition of GST-tagged ErbB2 expressed in sf9 cells by ELISA
    		[PMID: 22621397]
    Sf9 IC50
    6 nM
    Compound: 25, PF-00299804
    Inhibition of GST-tagged EGFR expressed in sf9 cells by ELISA
    Inhibition of GST-tagged EGFR expressed in sf9 cells by ELISA
    		[PMID: 22621397]
    Sf9 IC50
    74 nM
    Compound: 25, PF-00299804
    Inhibition of GST-tagged ErbB4 expressed in sf9 cells by ELISA
    Inhibition of GST-tagged ErbB4 expressed in sf9 cells by ELISA
    		[PMID: 22621397]
    Clinical Trial
    Molecular Weight

    487.95

    Formula

    C24H27ClFN5O3
    CAS No.
    Appearance

    Solid

    Color

    White to light yellow

    SMILES

    O=C(/C=C/CN1CCCCC1)NC2=CC3=C(C=C2OC)N=CN=C3NC4=CC=C(C(Cl)=C4)F.O
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMF : 10 mg/mL (20.49 mM; Need ultrasonic)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.0494 mL 10.2470 mL 20.4939 mL
    5 mM 0.4099 mL 2.0494 mL 4.0988 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMF    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 1 mg/mL (2.05 mM); Clear solution

    • Protocol 2

      Add each solvent one by one:  10% DMF    90% Corn Oil

      Solubility: ≥ 1 mg/mL (2.05 mM); Clear solution

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    Purity & Documentation
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMF 1 mM 2.0494 mL 10.2470 mL 20.4939 mL 51.2348 mL
    5 mM 0.4099 mL 2.0494 mL 4.0988 mL 10.2470 mL
    10 mM 0.2049 mL 1.0247 mL 2.0494 mL 5.1235 mL
    15 mM 0.1366 mL 0.6831 mL 1.3663 mL 3.4157 mL
    20 mM 0.1025 mL 0.5123 mL 1.0247 mL 2.5617 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Dacomitinib hydrate Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Dacomitinib1042385-75-0PF-00299804PF-299804PF00299804PF 00299804PF299804PF 299804EGFREpidermal growth factor receptorErbB-1HER1NSCLCcancertumorInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Dacomitinib hydrate
    Cat. No.:
    HY-118263
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.